2019
Awareness of Suicide Prevention Programs Among U.S. Military Veterans
Tsai J, Snitkin M, Trevisan L, Kraus SW, Pietrzak RH. Awareness of Suicide Prevention Programs Among U.S. Military Veterans. Administration And Policy In Mental Health And Mental Health Services Research 2019, 47: 115-125. PMID: 31529286, DOI: 10.1007/s10488-019-00975-6.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAwarenessComorbidityFemaleHealth PromotionHealth StatusHotlinesHumansMaleMental HealthMiddle AgedPatient Acceptance of Health CareSex FactorsSocial AdjustmentSocial StigmaSocial SupportSocioeconomic FactorsStress Disorders, Post-TraumaticSuicidal IdeationSuicide PreventionSuicide, AttemptedUnited StatesVeteransYoung AdultConceptsSuicide prevention programsVeterans Crisis LinePrevention programsVeterans AffairsVA centersMedical conditionsSuicide preventionPrimary healthcare providersPosttraumatic stress disorderMajority of veteransU.S. military veteransHistory of suicidalityCrisis lineVeteran populationHealthcare providersSuicidal ideationU.S. veteransPast homelessnessStress disorderAnxiety disordersVeteran suicideMilitary veteransTargeted outreachVeteransPrevention
2011
Noradrenergic vs Serotonergic Antidepressant with or without Naltrexone for Veterans with PTSD and Comorbid Alcohol Dependence
Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, Krystal JH. Noradrenergic vs Serotonergic Antidepressant with or without Naltrexone for Veterans with PTSD and Comorbid Alcohol Dependence. Neuropsychopharmacology 2011, 37: 996-1004. PMID: 22089316, PMCID: PMC3280636, DOI: 10.1038/npp.2011.283.Peer-Reviewed Original ResearchConceptsPost-traumatic stress disorderSerotonin uptake inhibitorNorepinephrine uptake inhibitorUptake inhibitorAlcohol dependenceMale veteransTreatment of PTSDUse outcomesSymptoms of PTSDDouble-blind conditionsMain outcome measuresEvidence of efficacyComorbid alcohol dependenceCurrent diagnostic criteriaAlcohol use disorderAlcohol use outcomesComorbid conditionsAdjunctive efficacyOutcome measuresOnly FDADiagnostic criteriaUse disordersClinical advantagesAlcohol consumptionDrug Administration